Genome-wide analyses of human lung adenocarcinoma have identified regions of consistent copy-number gain or loss, but in many cases the oncogenes and tumor suppressors presumed to reside in these loci remain to be determined. Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors. Single, double or triple compound loss of these genes in mice results in lung cancer, with penetrance and latency dependent on the number of lost Dok alleles. Cancer development is preceded by an aberrant expansion and signaling profile of alveolar type II cells and bronchioalveolar stem cells. In human lung adenocarcinoma, we identify DOK2 as a target of copy-number loss and mRNA downregulation and find that DOK2 suppresses lung cancer cell proliferation in vitro and in vivo. Given the genomic localization of DOK2, we propose it as an 8p21.3 haploinsufficient human lung tumor suppressor.
A r t i c l e s
DOK1, DOK2 and DOK3 are adaptor proteins that function in feedback loops to modulate tyrosine kinase signaling. DOK1, also known as p62 dok , is the prototypical DOK family member. It was cloned as the major phosphorylation substrate of the p210 bcr-abl oncoprotein in Philadelphia chromosome-positive chronic myelogenous leukemia blasts 1, 2 and is a substrate of many endogenous protein tyrosine kinases. To date, six additional DOK family members, DOK2 to DOK7, have been identified in human and mouse [3] [4] [5] [6] [7] . DOK1, DOK2 and DOK3 comprise a closely related subfamily 5 , and overexpression of these adaptor proteins in cultured cells negatively regulates ERK 4, [8] [9] [10] and MYC 11, 12 downstream of RAS and protein tyrosine kinases. DOK1, DOK2 and DOK3 are substrates of dozens of crucial protein tyrosine kinases, including epidermal growth factor receptor 10 , platelet-derived growth factor receptor 12 and c-Kit 1 . Because tyrosine phosphorylation of DOK proteins is required for their function as signaling adaptors, DOK1, DOK2 and DOK3 are believed to function in negative-feedback signaling loops that tightly modulate the duration and intensity of growth factor signaling.
We speculated that DOK genes act as tumor suppressors in solid tissues and in the hematopoietic compartment, where Dok1 and Dok2 have been shown to oppose BCR-ABL-driven leukemogenesis in mice 13, 14 . Using an in vivo genetic approach in the mouse, we discovered that Dok1, Dok2 and Dok3 act as tumor suppressors in the lung through their ability to regulate the biology of alveolar type II (AT2) cells and bronchioalveolar stem cells (BASCs). In addition, in a multifaceted analysis of human lung adenocarcinoma samples, we found frequent loss and downregulation of DOK2, consistent with a tumor-suppressive role for DOK2 in human cancer.
RESULTS

Dok single-and compound-knockout mice develop lung cancer
The biological functions of Dok1, Dok2 and Dok3 have been studied primarily in the hematopoietic system. To determine whether these genes have functions in other tissues, we investigated the expression of Dok1, Dok2 and Dok3 mRNA in a panel of mouse tissues. In addition to high expression in the spleen, the mRNAs of all three Dok family members were expressed at high levels in the lung 3 ( Supplementary  Fig. 1a ). Western blot analysis confirmed expression of Dok1, Dok2 and Dok3 protein in this tissue (Fig. 1a) .
We previously generated Dok1 and Dok2 knockout mice for investigation of their hematopoietic phenotype 9, 14 . Notably, when we analyzed the lungs of these mice, we discovered that many developed lung adenocarcinoma (see below). To further investigate the function of Dok family members as tumor suppressors, we generated Dok3 knockout mice using a homologous recombination targeting strategy in which a green fluorescent protein (GFP) cassette was inserted into the locus in frame with Dok3 ( Fig. 1b and Supplementary  Fig. 1b-e) . Because no GFP expression was detected in the Dok3 knockout lung or peripheral blood (Supplementary Fig. 1f ), we concluded that no stable peptide was produced from the Dok3 locus in the targeted mice.
As in the case of Dok1 or Dok2 disruption 8, 9, 13, 14 , Dok3 inactivation resulted in a lack of Dok3 protein expression without compensatory upregulation of other Dok proteins (see Fig. 1a ). Dok3 knockout mice were born in mendelian frequencies and showed no gross hematopoietic defects (M.N., unpublished data). In standard methylcellulose colony-forming assays, bone marrow progenitors from Dok3 knockout mutants yielded numbers of erythroid and myeloid colonies comparable to those from wild-type, sex-matched littermates (Supplementary Fig. 1g) .
Examination of the lungs of the Dok3 knockout mice, as well as the Dok1 and Dok2 single-knockout mice, revealed that mice of all knockout genotypes develop lung adenocarcinoma ( Fig. 1c and Table 1 ; P < 0.05 by Fisher's exact test of the overall incidence of lung adenocarcinoma at 11-25 months in each single-knockout genotype compared to wild type). The similar amino acid sequences of the Dok proteins, as well as prior evidence in the hematopoietic compartment 13, 14 , suggested that Dok1, Dok2 and Dok3 have partially redundant or overlapping functions. We therefore crossed the Dok3 knockout mice with the Dok1 and Dok2 knockout mice that we previously described 9, 14 to generate compound double-knockout (DKO) and triple-knockout (TKO) mutants on a pure 129S1/SvImj genetic background 9, 14 . Similar to the single mutants, the compound mutants were fertile and pathologically normal at birth. However, as early as 6 weeks after birth, 30% of TKO mice developed small lung tumors (n = 10). An analysis of 324 mice at 11-25 months of age revealed that all single and compound mutant genotypes develop lung adenocarcinoma at moderate to high (24-64%) penetrance ( Fig. 1c and Table 1) . Lung adenocarcinoma incidence increased with each lost Dok allele, with the highest incidence in the TKO mice at all time points. In addition, both the Dok TKO and the Dok2/Dok3 DKO mice had a survival defect, with mice beginning to die at ~1 year (Supplementary Fig. 2) .
Dok knockout lungs often contained multiple large tumor nodules (Fig. 2a) . Hematoxylin and eosin (H&E) staining and pathological analysis showed that all cases were adenocarcinomas, often with papillary and solid growth patterns (Fig. 2b) . Nuclei showed open chromatin, some with prominent nucleoli. Tumor cells showed nuclear inclusions and increased nuclear-to-cytoplasmic ratios, with scattered cells showing nuclear pleomorphism. We observed mitotic figures and an elevated frequency of mitotic cells positive for phosphorylated histone H3 (Fig. 2c,d) , as well as vascular invasion and multiple tumor nodules. We did not find gross lymph-node metastases, although lymph nodes were not systematically sampled. Inflammatory infiltrate composed of lymphocytes and macrophages was evident in many tumors, ranging from mild to marked. Tumors were, in general, well differentiated rather than poorly differentiated. To assess whether these tumors were primary and not secondary from another organ, we conducted a standard 15 immunohistochemical assessment using an antibody to thyroid transcription factor-1 (TTF-1). All tumors analyzed were positive for TTF-1 (Fig. 2e) , indicating that the tumors were primary lung cancers. Given the role of Dok1, Dok2 and Dok3 in regulation of receptor tyrosine kinase and Ras signaling, we conducted immunohistochemical analyses with 
A r t i c l e s
antibodies to phosphorylated Erk1/2 and phosphorylated Akt to determine whether loss of Dok expression in the lung leads to abnormal Erk or Akt activation (Fig. 2f,g ). Compared to wild-type lung tissue, tumors in Dok mutants showed moderate staining for phosphorylated Akt (Fig. 2f) and strong staining for phosphorylated Erk (Fig. 2g) .
Expansion of AT2 cells and BASCs precedes tumorigenesis
It has recently been proposed that hallmark stem cell qualities, such as self-renewal, pluripotency and resistance to injury, could promote and maintain tumorigenesis if gone awry 16, 17 . In this regard, BASCs have been identified as putative stem cells in the mouse lung that are associated with adenocarcinoma development 18 . To investigate the histogenesis of the Dok mutant lung tumors, we conducted immunohistochemical analyses using antibodies to Clara cell secretory protein (CCSP) and prosurfactant protein C (proSP-C), commonly used markers that distinguish between Clara cells and AT2 cells, respectively (Fig. 3a,b) . Tumor regions were predominantly positive for proSP-C (Fig. 3a) . As expected, CCSP staining was seen in the cells lining the bronchioles (Fig. 3b, left) . Tumor regions, however, were predominantly negative for CCSP (Fig. 3b, middle) , with a few scattered cells showing positive staining for CCSP (Fig. 3b, right) . This staining pattern suggested that the tumors were likely to have arisen from AT2 cells or their progenitors, BASCs. BASCs are a unique subpopulation of lung cells that express both the AT2 marker proSP-C and the Clara cell marker CCSP. We carried out double immunofluorescence staining for these markers in the lungs of 12-week-old wild-type and TKO mice. At this time point, the majority of TKO mice have not yet developed tumors, and a diffuse hyperplasia is often observed, as shown by H&E staining (Fig. 3c) . Similar to the tumors in older TKO mice, hyperplastic regions in young TKO mice were composed primarily of proSP-C + AT2 cells (Fig. 3d, left) . Further examination of the TKO immunofluorescence sections at high magnification, however, revealed a marked increase in the frequency of proSP-C + CCSP + BASCs, which were not only located at their correct anatomic position-the bronchioalveolar duct junction-but also aberrantly scattered throughout the TKO alveolar hyperplasia (Fig. 3d , middle and right). In contrast, we did not find BASCs in the alveoli of wild-type mice (Fig. 3d , middle and right).
To quantify this phenotype and to determine whether Dok genes are indeed expressed in these specific cellular compartments, we dissociated mouse lung cells and used an established BASC flow cytometry sorting strategy 18 (see Online Methods and Supplementary Fig. 3a) . Notably, cell dissociation consistently yielded more cells from TKO lungs than from age-matched, wild-type lungs, although the overall weights of the mice did not differ (data not shown). To ensure that we were measuring pulmonary cells and not other cell types, we estimated the cellularity after using flow cytometry to exclude cells positive for the endothelial marker PECAM-1 and the hematopoietic marker CD45. This analysis confirmed that TKO mice had a significantly higher number of total lung cells than did age-matched, wild-type mice ( Fig. 4a , P < 0.01).
We next used the BASC sorting strategy to quantify and purify three populations of lung calls negative for PECAM-1 and CD45. The first population (referred to as R5) contained mostly unidentified cells and Clara cells, whereas R6 and R7 contained AT2 cells and BASCs, respectively. We confirmed the purity of each fraction by immunofluorescence staining for proSP-C and CCSP (Fig. 4b) . Consistent with the immunofluorescence data, flow cytometric analysis revealed an expansion of the Sca-1 + BASC population (R7) and highly autofluorescent AT2 cell population (R6) in TKO lungs compared to wild-type lungs (Fig. 4c,d) . The expansion involved a significant increase in the percentages (Fig. 4c , left) and absolute numbers (Fig. 4c, right ) of AT2 cells (P < 0.01) and BASCs (P < 0.05). The absolute number of R5 cells was not significantly altered in the TKO cohort (P = 0.24), indicating that the effect of Dok inactivation was specific to a subset of pulmonary cells.
To determine the expression of Dok genes in these cell populations, we used flow cytometry to collect fractions from wild-type lungs for protein or RNA isolation. Using western blotting and quantitative RT-PCR, we detected Dok1, Dok2 and Dok3 protein and mRNA in the BASC fraction (R7; Fig. 4e,f and Supplementary Fig. 3b) .
We previously identified high levels of Akt and Erk phosphorylation in tumors from Dok mutant mice (see Fig. 2f,g ). To further elucidate whether Akt and Erk activation precedes tumor formation in Dok TKO mice, we isolated BASCs and AT2 cells from wild-type and Dok TKO mice and analyzed the levels of Akt and Erk phosphorylation at the same time point used for the above analyses. BASCs ( Fig. 4g ) and AT2 cells (Fig. 4h) from Dok TKO mice showed higher levels of Erk phosphorylation than did cells isolated from wildtype mice. Furthermore, BASCs from TKO lungs showed markedly higher levels of phosphorylated Akt than did BASCs from wild-type lungs. Erk and Akt were therefore activated in lung epithelial cells of Dok TKO mice before tumor formation, supporting a direct role for Dok family proteins in regulation of Erk and Akt signaling in the mouse lung.
Together, these data are consistent with a model of tumorigenesis whereby combinatorial Dok1, Dok2 and Dok3 inactivation leads to hyperactivation of Akt and Erk and an expansion of BASCs with subsequent differentiation into AT2 cells. Although we cannot exclude the possibility that the tumors originated from AT2 cells, or from both AT2 cells and BASCs, our analysis further associated aberrant BASC expansion with preneoplastic and neoplastic lung transformations in the mouse (see Discussion).
Loss of DOK2 expression in human lung cancer
To assess the relevance of these findings to human lung adenocarcinoma, we evaluated the genomic status of DOK1, DOK2 and DOK3 in an array-based comparative genomic hybridization (aCGH) dataset 19 of 199 primary human lung adenocarcinoma samples. Notably, the DOK2 gene is localized to chromosome 8p21.3, one of the regions most frequently deleted in human lung cancer [19] [20] [21] [22] and a region long hypothesized to contain one or more tumor suppressor genes 21, 22 . In this dataset, one copy of DOK2 was lost in 37% of tumor samples (Fig. 5a ) whereas DOK1 and DOK3, located at 2p13.1 and 5q35.3, were lost in 1.5% and 7% of cases, respectively. These data are broadly consistent with a recent genome-wide analysis of human lung adenocarcinoma that found frequent deletions of 8p (containing DOK2) 20 . To further validate the aCGH findings, we analyzed a SNP array of 21 primary human non-small-cell lung cancers. Consistent with the aCGH analysis, one copy of DOK2 was lost in 7 (33%) of 21 cases (Supplementary Fig. 4) .
We next evaluated the consequences of this genomic loss on DOK2 expression. To this end, we analyzed the mRNA expression of DOK1, DOK2 and DOK3 in primary and metastatic human lung cancers, lung cancer cell lines and normal human lung tissue using microarray-based expression profiling. In agreement with the aCGH data, expression analysis identified DOK2 as a target of significant mRNA downregulation in primary lung adenocarcinoma, lymph node metastases and lung cancer cell lines compared to normal, noncancerous human lung tissue (Fig. 5b) . In contrast, we observed no significant reduction of DOK1 or DOK3 mRNA expression in the primary tumors, although expression of DOK3 was decreased in lymph node metastases compared to normal lung (Supplementary Fig. 5a ). DOK2 mRNA expression was associated with DOK2 copy-number loss, with significantly lower DOK2 expression seen in tumors with DOK2 loss than in those without DOK2 loss (P < 0.05; Supplementary  Fig. 5b ). Further validating our finding of decreased DOK2 expression, a search of the microarray database Oncomine 23 revealed two independent studies 24, 25 that confirmed the finding of DOK2 mRNA downregulation in human lung adenocarcinoma ( Supplementary  Fig. 5c ). Given the high rate of copy-number alteration and mRNA downregulation of DOK2, but not DOK1 or DOK3, we focused on DOK2 in our further studies of the role of DOK family members in human lung cancer.
To assess the consequences of DOK2 mRNA downregulation on DOK2 protein levels in human lung cancer, we analyzed DOK2 A r t i c l e s protein in primary lung cancer specimens and cell lines. We observed a reduction of DOK2 protein in tumor tissue from patients with lung cancer compared to the adjacent, noninvolved normal lung in the same patients (Fig. 5c) . Similarly, DOK2 protein expression in lung cancer cell lines was either low or undetectable ( Fig. 5d and Supplementary  Fig. 5d ). Moreover, tumor tissue microarray analysis of more than 80 lung tumors revealed low or undetectable expression of DOK2 protein in a substantial majority of samples, whereas expression of DOK1 and DOK3 was usually maintained (Supplementary Fig. 5e ).
DOK2 inhibits lung tumor proliferation in vitro and in vivo
The identification of DOK2 downregulation and loss in human lung cancer is consistent with a tumor-suppressive role for DOK2 in the lung. To assess whether DOK2 inhibits proliferation of lung cancer cells, we conducted add-back experiments in which we stably overexpressed DOK2 in the lung cancer cell line H1299, which normally does not express detectable levels of DOK2. In a classical growthcurve assay, cells expressing DOK2 had an impaired growth rate compared to that of cells transfected with empty vector (Fig. 6a) . Similar to our findings in the mouse setting, where Dok knockout lung tumors (Fig. 2f,g ) and BASCs (Fig. 4g,h) showed activation of Erk and Akt, H1299 cells without DOK2 expression showed markedly higher serum-induced phosphorylation of Erk and Akt than did cells with forced DOK2 expression (Fig. 6b) . A xenograft assay in immunocompromised mice confirmed that DOK2 expression suppresses the growth of H1299 cells in vivo (Fig. 6c,d) . These functional data, together with the mouse genetic analyses and the observation that DOK2 is a target of frequent genomic loss and downregulation in human lung cancer, implicated DOK2 as a human lung tumor suppressor. in four of four tumors (Fig. 7b) , indicating that loss of the wildtype allele is not required for tumor development, although we cannot presently exclude mutation or silencing of the remaining allele. These data are similar to the human cancer scenario, where we did not observe homozygous deletions of the DOK2 locus, suggesting that Dok2 is haploinsufficient in its tumor-suppressive function. We therefore concluded that Dok2 heterozygosity alone can promote lung cancer and that human DOK2 should be considered a crucial target of 8p loss in human lung adenocarcinoma.
Lung cancer susceptibility in
DISCUSSION
Here we present a comprehensive analysis of the single and combinatorial functions of the Dok family members Dok1, Dok2 and Dok3 in lung tumor suppression. We found that either heterozygous loss (in the case of Dok2) or complete loss of a single Dok gene can promote tumorigenesis. In addition, Dok1, Dok2 and Dok3 have overlapping functions and can cooperate in lung tumor suppression, as combinatorial knockout of all three Dok genes strongly promotes lung tumor formation in vivo.
We elucidated the changes in cell biology that result from Dok inactivation in vivo, specifically perturbations of the AT2 and BASC cellular compartments that occur in the lungs of Dok TKO mice before frank tumorigenesis. BASC expansion has been associated with lung tumorigenesis in a number of mouse models 18, [26] [27] [28] [29] , but the role of BASCs as cancer-initiating cells for lung cancer remains to be definitively established. Nonetheless, our data show that combinatorial loss of Dok1, Dok2 and Dok3 perturbs BASC and AT2 signaling pathways and homeostasis. 
A r t i c l e s
Although Dok single-and compound-mutant mice develop a range of immune [30] [31] [32] [33] [34] and leukemia 13, 14 phenotypes, several pieces of evidence support a cell-autonomous mechanism of lung tumorigenesis in Dok mutant mice. First, the kinetics of the chronic myelogenous leukemia-like myeloproliferative disorder and lung phenotype are different in Dok TKO mice, with the onset of lung cancer (as early as 6 weeks) preceding the onset of leukemia, in which the expansion of the myeloid compartment becomes apparent at ~1 year of age with incomplete penetrance (see Supplementary  Fig. 6 ). Second, the immune phenotypes of the Dok1 (refs. 33,34), Dok2 and Dok3 (ref. 32) knockout mice are distinct, owing to the cell lineage-dependent expression of these genes in the hematopoietic compartment. In contrast, mice of all three single-knockout genotypes develop lung cancer. Third, all three Dok genes are expressed in BASCs, and these cells show aberrant activation of Erk and Akt in Dok TKO mice. Fourth, enforced overexpression of DOK2 inhibits the growth of human lung cancer cells in vitro and after xenograft. Together, these facts indicate that Dok knockout mice are likely to develop lung cancer as a result of cell-autonomous deregulation of Erk and Akt signaling after loss of Dok expression in lung epithelial and progenitor cells.
Notably, we show that DOK2 is the target of frequent copy-number loss in human lung cancer and that this genomic loss is accompanied by downregulation of DOK2 mRNA expression, supportive of a tumor-suppressive role for this gene. Moreover, heterozygous loss of DOK2 alone can promote lung tumorigenesis, as indicated by the fact that Dok2 heterozygous mice also develop lung cancer, and this occurs in the absence of loss of heterozygosity. These data suggest that DOK2 is a haploinsufficient human lung tumor suppressor.
Recent genome-wide analyses of copy-number variation in human lung cancer have provided comprehensive descriptions of the genetic landscape of human cancer 19, 20, 35 . However, the success of this approach in identifying tumor suppressors and oncogenes has been limited to loci subject to focal deletion and focal amplification, which represent only a portion of the genome 20 . Other regions of the genome, including 8p, are consistently targeted by broadscale deletions 20 , and it is now believed that regions of broad losses may encompass multiple, rather than single, tumor suppressors 19 . Given these observations, many groups have proposed that at least two to three tumor suppressors may reside on 8p, including at least one tumor suppressor in the 8p21.3 locus, and that the simultaneous compound loss of these tumor suppressors may be required for tumorigenesis 19, [36] [37] [38] [39] . In this context, our findings identify DOK2 as an 8p21.3 tumor suppressor, and the possible cooperative tumorigenic effect of compound haploinsufficiency of DOK2 and other putative 8p tumor suppressors, such as DUSP4 (ref. 19) , should be investigated (Supplementary Fig. 7) .
Our work emphasizes the key role of mouse molecular genetics in identifying and validating candidate tumor suppressor genes in broad-scale deleted regions. This in vivo approach in the mouse proves even more necessary and decisive when tumor suppressor haploinsufficiency and compound haploinsufficiency are suggested to represent the driving forces underlying human tumorigenesis. 
METHODS
ONLINE METHODS
Generation of Dok3 mutant mice, DKO and TKO mutants. To generate the targeting construct, a 4.1-kb SmaI-KpnI fragment and a 3.8-kb HindIII-SalI fragment corresponding to the Dok3 locus were subcloned into the pPNT vector (Fig. 1b) . The construct was linearized with NotI and electroporated into embryonic stem cells with a 129S1/SvImj background (CJ7). Transfectants were selected in G418 (350 µg/ml) and ganciclovir (2 µM) and expanded for Southern blot analysis using a 5′ probe and a 3′ probe (Supplementary Fig. 1 ). Chimeric mice were produced and then mated with 129S1/SvImj females (The Jackson Laboratories) to obtain Dok3 mutants in a 129S1/SvImj background. Dok1 knockout mice, Dok2 knockout mice and Dok1/Dok2 DKO mice have been previously described 3, 14 . Peripheral blood analysis. Peripheral blood was obtained from tail veins and then used for flow cytometry or blood count analysis. For flow cytometry, cells were incubated with antibodies to Mac-1 and GR-1 (BD Biosciences), and red blood cells were lysed using FACS lysing solution (BD Biosciences). Cells were analyzed using a BD FACScan flow cytometer and FlowJo software. For blood count analysis, peripheral blood was diluted 1:10 in PBS, and blood counts done using an Advia 120 Hematology Analyzer (Bayer).
Flow cytometry. Preparation of single-cell suspensions from lungs and staining were done as described 18 using antibodies to Sca-1 (FITC conjugated), PECAM (APC conjugated) and CD45 (APC conjugated; BD Biosciences). Staining with DAPI (Molecular Probes) was used to eliminate dead cells. Cell sorting was done with a MoFlo (DakoCytomation), and data were analyzed with Cytomation Summit or FlowJo software. For western blotting of sorted cells (Fig. 4g,h ), cells were sorted directly into 2× SDS sample loading buffer.
Immunofluorescence. Immunostaining for proSP-C and CCSP was done on frozen lung sections or flow cytometry-sorted cells using antisera raised against CCSP (1:100; T-18, Santa Cruz Biotechnology) or pro-SP-C (1:100; 3786, Chemicon). Cells were sorted onto poly-l-lysine-coated microscope slides, fixed with 4% paraformaldehyde, and permeabilized with PBS containing 0.1% Triton X-100. Cells were incubated with primary antibodies overnight at 4 °C, followed by secondary detection using Alexa Fluor-conjugated secondary antibodies (Invitrogen), mounting and nuclear counterstaining using Vectashield with DAPI (Vector Labs).
Fluorescence microscopy. Images were acquired with either with a Leica TCS AOBS SP2 laser scanning confocal microscope (Fig. 3d) or an Olympus BX60F microscope (Fig. 4b) . Postacquisition image processing was done using Adobe Photoshop.
Patient samples. Full details regarding lung tumor sample acquisition and selection have been previously described 19 . Briefly, tumor tissue was collected at the time of resection from patients with primary lung adenocarcinoma operated on at Memorial Sloan-Kettering Cancer Center (MSKCC), mainly between 1996 and 2006, under protocols approved by the MSKCC Institutional Review Board. Informed consent was obtained from all patients, except for experiments determined to by the MSKCC Institutional Review Board to be exempt. The tissues were snap-frozen in liquid nitrogen and stored at −80 °C.
Array CGH analysis.
For aCGH analysis of the genomic status of DOK genes, we used an aCGH dataset of 199 primary human lung adenocarcinoma samples 19 generated using Agilent 44K oligonucleotide arrays.
SNP array analysis. Affymetrix 100K SNP chips were used to generate the SNP data. The Affymetrix copy-number analysis tool was used to compute the copy number and then convert it to an effective log (base 2) ratio. To find amplified and deleted segments, the circular binary segmentation method 2 was used. The data were locally smoothed and then segmented using an alpha value of 0.01.
Microarray analysis of DOK mRNA in primary human lung cancer. Microarrays for analysis of DOK mRNA expression were prepared as previously described 19, 40 .
Quantitative real-time RT-PCR. RNA was collected using TRIzol (Invitrogen) and reverse-transcribed with random primers using the QuantiTect reversetranscription kit (Qiagen). Quantitative RT-PCR reactions were prepared using the QuantiTect SYBR Green PCR kit (Qiagen) and gene-specific primers (see below), and reactions were run in duplicate on a LightCycler (Roche) or iCycler (BioRad). Primer design, melting curve analysis, blank samples and ethidium bromide agarose gel migration were used to ensure the specificity and integrity of the products acquired. Primers specific for mouse Dok genes and a control locus ( Fig. 4f and Supplementary Fig. 3b ) are shown in Supplementary Table 1 .
Laser-capture microdissection. Lungs from Dok2 +/-mice were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned and stained with H&E. Tumor cells and cells from adjacent noninvolved normal lung tissue were isolated using an ArcturusXT microdissection system. DNA was isolated using a Pico Pure DNA extraction kit (Arcturus). PCR analysis of the DNA was done using primer sets that discriminate between the wild-type and targeted alleles. Primers used are shown in Supplementary Table 2 .
Retrovirus production and growth-curve analysis. Full-length human DOK2 cDNA was subcloned into the MIGR1 retroviral vector to generate MIG-hDOK2.
